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RANKL, TGF-β andWntβ-catenin; these pathways may alter homeosta-
sis of neighbouring tissues and affect the function of the joint unit as a
whole (Yuan et al., 2014). The biomarker CTX-II has been detected at
the bone-cartilage interface and is associated with osteophyte forma-
tion (Bay-Jensen et al., 2008). It has also been suggested that changes
in the uCTX-II level may reﬂect the functional bone-cartilage unit, indi-Articular cartilage
Subchondral bone
Proteomics
OsteoarthritisOsteoarthritis (OA) is the most common age-related degenerative
joint disorder. It is considered a disease of the entire joint, which is
not simply a result of attrition but rather abnormal remodelling and co-
alescent failure of multiple tissues. Despite the prevalence of OA, thera-
peutic strategies are currently limited to the treatment of pain and
inﬂammation. New disease-modifying agents that slow progression
anddiagnostic biomarkers are urgently required. Given the lack of treat-
ment options to repair degradation of articular cartilage, anti-resorptive
agents and anabolics, such as bisphosphonates, are candidate treat-
ments for OA (Karsdal et al., 2014). An optimal treatment for OA will
likely target at least two joint tissues, yet the factors that govern the
bone-cartilage interactions during pathogenesis remain largely
unknown.
The bone-cartilage interface is an important synergistic unit
consisting of the area between the deep layers of articular cartilage
and the underlying subchondral bone (Yuan et al., 2014). The close
physical association between subchondral bone and cartilage allows in-
teraction and suggests biochemical and molecular crosstalk may con-
tribute to OA pathology (Goldring, 2012). Crosstalk is elevated at the
osteoarthritic bone-cartilage juncture due to osteochondral angiogene-
sis and bone remodelling (Fig. 1). Vascular invasion from bone into car-
tilage and development of microcracks and ﬁssures provide pathways
for communication (Li et al., 2013). Alterations in either bone or carti-l Sciences, University of Surrey,
eri).
. This is an open access article underlage can modulate signalling pathways including HIF-2α, OPG/RANK/
cating the importance of crosstalk in OA pathophysiology (Lories and
Luyten, 2011). The role of the crosstalk in the progression of OA requires
additional investigation using genomics, epigenetics, proteomics and
metabolomics approaches.
Proteomic technologies make it possible to identify factors involved
in OA progression and build a library of mediators. Studies have re-
vealed numerous cytokines, proteases, and matrix fragments in serum,
synovial ﬂuid, and articular cartilage of OA patients. However, little in-
formation is currently available regarding the protein proﬁles of distur-
bances in subchondral bone or bone-cartilage crosstalk (Boris Chan et
al., 2015). Gene expression proﬁles of subchondral bone isolated from
early experimental OA have identiﬁed dysregulated genes with roles
in bone and cartilage development, remodelling and degeneration
(Zhang et al., 2012). That study indicates the importance of further in-
vestigations into the subchondral bone using high-throughput protein
analyses. Additionally, transcriptome-proteome combined study of OA
synovial tissue revealed that gene expression changes do not always co-
incidewith protein levels, this again demonstrates the need for compre-
hensive proteome studies of subchondral bone to validate
transcriptomics (Lorenz et al., 2003).
It is technically challenging to extract proteins of interest from bone
due to the abundance of collagens andminerals. A pilot study usingHCl/
Urea extraction identiﬁed 119 proteins in OA subchondral bone with
only 7 proteins shared between the low and high damage regions.
This data suggests that signalling pathways in the corresponding
subchondral bone region may relate to OA severity (Boris Chan et al.,
2015). However, validation is required with the authors acknowledging
that the regional variations could be due to experimental error.
Bone–cartilage communicationmodels are needed to elucidate solu-
ble mediators. Previously we have employed a cartilage explant model
system to investigate the secretome of cartilage in response to inﬂam-
matory stimuli (Williams et al., 2013). A similar model system is re-
quired using osteochondral co-cultured explants to identify novelthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Molecules involved in crosstalk at the bone–cartilage interface during osteoarthritis (OA) development and progression. Genes with altered expression proﬁles in an early
experimental OA model include transforming growth factor β1 (TGFβ1), insulin-like growth factor-1 (IGF1), bone morphogenic protein-5 (BMP5), matrix metalloproteinase-3
(MMP3), alkaline phosphatase (ALP), collagen type 1 (Col1a1) and type 2 (Col2a1), interleukin-1β (IL1β) and Indian hedgehog (Ihh). Note that the list is not exhaustive.
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the bone-cartilage juncture is intact. Recently an in vitro three-dimen-
sional microsystem that models the osteochondral unit was developed.
Osteogenic and chondrogenic tissues were produced using mesenchy-
mal stem cells seeded within biomaterial scaffolds in a multichamber
bioreactor (Lin et al., 2014). Tissue-speciﬁc gene expression,matrix pro-
duction and a basophilic developing tidemark were detected. Introduc-
tion of interleukin-1β (IL-1β) to either the chondral or osseousmedium
induced strong degradative responses both locally and in the opposing
tissue type. IL-1β treatment of the osseous compartment resulted in a
stronger catabolic response in the chondral layer than direct IL-1β ap-
plication to the chondral component. This study provides evidence for
active biochemical communication across the bone-cartilage interface
and supports the osteochondral nature of OA (Lin et al., 2014).
Development of cell based model systems will allow investigation
into the release of soluble factors by stimulated osteoblasts/osteocytes
that can induce a pro-catabolic phenotype in chondrocytes. An iTRAQ
secretome analysis revealed that a soluble protein (14-3-3ε) was differ-
entially present when a mechanical stress was applied on osteoblasts
and that these secreted mediators could activate chondrocytes to pro-
duce metalloproteinases (Priam et al., 2013).
In conclusion, molecular studies of crosstalk at the bone–cartilage
interface will aid our understanding of the pathophysiology of OA and
advance therapeutic approaches. This will facilitate the development
of novel drugs and agents that speciﬁcally block mechanisms of
crosstalk responsible for the structural changes in OA and provide a
novel system for biomarker discovery.Conﬂict of Interest Statement
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